Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia

被引:14
作者
Visser, J
van Baarle, D
Hoogeboom, BN
Reesink, N
Klip, H
Schuuring, E
Nijhuis, E
Pawlita, M
Bungener, L
de Vries-Idema, J
Nijman, H
Miedema, F
Daemen, T
van der Zee, A
机构
[1] Univ Groningen, Med Ctr, Dept Gynecol, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Med Ctr, Dept Med Microbiol, Mol Virol Sect, NL-9700 RB Groningen, Netherlands
[3] Univ Utrecht, Med Ctr, Dept Immunol, Utrecht, Netherlands
[4] Univ Groningen, Med Ctr, Dept Pathol, NL-9700 RB Groningen, Netherlands
[5] Deutsch Krebsforschungszentrum, Angewandte Tumorvirol, D-6900 Heidelberg, Germany
关键词
cervical cancer; IFN-gamma; HPV; CD4(+) T cell; CD8(+) T cell;
D O I
10.1002/ijc.21673
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
It has been suggested that local invasive procedures may alter the natural course of (pre)malignant cervical disease. This could be due to partial excision of the lesions, or via induction of cellular immunity against human papillomavirus (HPV) by the local invasive procedures. We studied the influence of local invasive procedures on HPV-16 E7 specific immune responses in patients with different grades of cervical intra-epithelial neoplasia (CIN) and different stages of cervical cancer. Blood was obtained at intake and after invasive procedures from patients with CIN or cervical cancer. Antigen specific T-cell responses were measured by IFN-gamma ELISPOT analysis, after stimulation with recombinant HPV-16 E7 protein. As expected, HPV-16 E7 specific IFN-gamma T cell responses were more frequent in HPV-16 DNA positive patients compared with that in HPV-16 DNA negative patients (39/50 vs. 16136, (p = 0.006, x(2) test). After invasive procedures, a small number of HPV-16 DNA positive CIN patients, but a considerable proportion of HPV-16 DNA positive cervical cancer patients, showed an enhancement of T cell responses against HPV-16 E7. Induction of T cell reactivity was most pronounced in cervical cancer patients who had undergone previous invasive procedures. Both CD4(+) and CD8(+) T cells showed E7 specific IFN-gamma production upon in-vitro stimulation. Our study shows that invasive procedures may enhance HPV-specific cell-mediated immunity in a considerable number of patients with cervical cancer, but in only a minority of CIN patients. Our data indicate that invasive procedures should be considered as possible confounding factors when analyzing the effectiveness of therapeutic immunization studies, especially, when induction of HPV-specific immune responses is used as intermediate end-point. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:2529 / 2537
页数:9
相关论文
共 36 条
[21]   Application of the IFN-γ ELISPOT assay to quantify T cell responses against proteins [J].
Schmittel, A ;
Keilholz, U ;
Bauer, S ;
Kuhne, U ;
Stevanovic, S ;
Thiel, E ;
Scheibenbogen, C .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 247 (1-2) :17-24
[22]   HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase [J].
Sehr, P ;
Müller, M ;
Höpfl, R ;
Widschwendter, A ;
Pawlita, M .
JOURNAL OF VIROLOGICAL METHODS, 2002, 106 (01) :61-70
[23]   A generic capture ELISA for recombinant proteins fused to glutathione S-transferase:: validation for HPV serology [J].
Sehr, P ;
Zumbach, K ;
Pawlita, M .
JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 253 (1-2) :153-162
[24]  
SHAH KV, 1995, FIELDS VIROLOGY, P2077
[25]   Human papillomavirus (HPV) type 16-specific CD8+T cell responses in women with high grade vulvar intraepithelial neoplasia [J].
Todd, RW ;
Roberts, S ;
Mann, CH ;
Luesley, DM ;
Gallimore, PH ;
Steele, JC .
INTERNATIONAL JOURNAL OF CANCER, 2004, 108 (06) :857-862
[26]   Detection of CD8+ T cell responses to human papillomavirus type 16 antigens in women using imiquimod as a treatment for high-grade vulval intraepithelial neoplasia [J].
Todd, RW ;
Steele, JC ;
Etherington, I ;
Luesley, DM .
GYNECOLOGIC ONCOLOGY, 2004, 92 (01) :167-174
[27]   The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development [J].
van der Burg, SH ;
de Jong, A ;
Welters, MJP ;
Offringa, R ;
Melief, CJM .
VIRUS RESEARCH, 2002, 89 (02) :275-284
[28]  
van der Burg SH, 2001, INT J CANCER, V91, P612, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1119>3.0.CO
[29]  
2-C
[30]  
Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt